COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab
Nefrologia (Engl Ed). 2021 May-Jun;41(3):354-356.
doi: 10.1016/j.nefro.2020.07.001.
Epub 2020 Jul 27.
[Article in
English,
Spanish]
Affiliations
- 1 Servicio de Nefrología, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, España.
- 2 Servicio de Nefrología, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, España; Grup de Nefrologia. Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, España.
- 3 Servicio de Medicina Interna, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, España.
- 4 Servicio de Nefrología, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, España; Grup de Nefrologia. Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, España. Electronic address: [email protected].
No abstract available
MeSH terms
-
Anti-Allergic Agents / therapeutic use*
-
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / complications*
-
COVID-19 / diagnosis*
-
COVID-19 Nucleic Acid Testing
-
Chronic Urticaria / drug therapy*
-
Female
-
Glomerulonephritis, Membranoproliferative / complications
-
Glucocorticoids / therapeutic use
-
Humans
-
Middle Aged
-
Omalizumab / therapeutic use*
-
Prednisone / therapeutic use
-
Renal Dialysis*
-
Renal Insufficiency, Chronic / etiology
-
Renal Insufficiency, Chronic / therapy*
-
Syndrome
Substances
-
Anti-Allergic Agents
-
Glucocorticoids
-
Omalizumab
-
Prednisone